The US Food and Drug Administration (USFDA) has approved Jubilant Pharmova’s commercial batch manufacturing of the first product on its new isolator-based fill-and-finish line (Line 3) at the Jubilant HollisterStier LLC (JHS) contract manufacturing facility in Spokane, Washington, USA.

Jubilant HollisterStier LLC is a step-down subsidiary of Jubilant Pharmova, held through Jubilant Pharma Holding Inc. and Jubilant Pharma Limited, Singapore. 

The Spokane facility offers end-to-end manufacturing support, from process qualification through commercial release, serving pharmaceutical and biopharmaceutical clients across North America.

Jubilant Pharmova operates across five business verticals: Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing (CDMO) of sterile injectables, Contract Research Development and Manufacturing (CRDMO), Generics, and Proprietary Novel Drugs. 

The company runs a network of 45 radiopharmacies in the US, sterile injectable manufacturing sites in Spokane (USA) and Montreal (Canada), and an FDA-approved API facility in Nanjangud, Karnataka.